+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD)



Neutral-pH peritoneal dialysis solution improves peritoneal function and decreases matrix metalloproteinase-2 (MMP-2) in patients undergoing continuous ambulatory peritoneal dialysis (CAPD)



Clinical and Experimental Nephrology 8(4): 339-343



Conventional lactate-buffered peritoneal dialysis (PD) solutions have several bioincompatible characteristics, including acidic pH, lactate buffer, and the presence of glucose degradation products (GDPs), and these characteristics contribute to membrane dysfunction in PD patients. The formation of GDPs can be reduced by separating the glucose component of the solution from the lactate component during sterilization. This study was carried out to evaluate the clinical effect of dual-chambered neutral-pH PD solution in patients on continuous ambulatory peritoneal dialysis (CAPD). Thirteen CAPD patients using conventional PD solution were enrolled in this study. The fast peritoneal equilibration test (fast PET) was performed periodically before and after treatment with neutral PD solution. The concentration of matrix metalloproteinase-2 (MMP-2) in dialysate effluent was measured using 4-h dwelling 2.5% glucose dialysis solution. The patients were categorized into two groups, according to the value of the initial dialysate/plasma (D/P) creatinine ratio: i.e., lower transporters (group L, D/PCr < 0.65) and higher transporters (group H, D/PCr >/= 0.65). The mean D/P creatinine ratio measured by fast PET, was significantly decreased (0.72 +/- 0.09 to 0.60 +/- 0.06; P < 0.03) after treatment with neutral PD solution in group H. The mean glucose level in 4-h dwelling dialysate effluent was elevated (824.6 +/- 195.9 mg/dl to 942.6 +/- 147.8 mg/dl; P < 0.022) in all subjects. In group H, a significant decrease of MMP-2 in the dialysate effluent was recognized from 15 months after the beginning of treatment with the neutral PD solution (141.4 +/- 52.5 ng/ml to 91.3 +/- 15.1 ng/ml; P < 0.05), with the lowest value being shown at 21 months (80.0 +/- 31.8 ng/ml; P < 0.03). Neutral-pH peritoneal dialysis solution decreased the MMP-2 level in dialysate and improved peritoneal function in high-transporter patients with CAPD treatment.

(PDF emailed within 0-6 h: $19.90)

Accession: 049677896

Download citation: RISBibTeXText

PMID: 15619033

DOI: 10.1007/s10157-004-0310-2


Related references

Adequate peritoneal dialysis: limitations of continuous ambulatory peritoneal dialysis (CAPD), place of automated peritoneal dialysis (APD). Nephrologie 19(5): 239-244, 1998

Matrix metalloproteinase levels in peritoneal effluents were increased in a patient with appendicitis undergoing continuous ambulatory peritoneal dialysis. Clinical and Experimental Nephrology 16(3): 501-504, 2012

Effect of amino acid based dialysis solution on peritoneal permeability and prostanoid generation in patients undergoing continuous ambulatory peritoneal dialysis. American Journal of Nephrology 12(1-2): 61-67, 1992

Comparison of two catheters for peritoneal access in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Scandinavian Journal of Urology and Nephrology 17(3): 343-346, 1983

Insulin in clearance kinetic studies on peritoneal membrane function in children undergoing continuous ambulatory peritoneal dialysis capd. European Journal of Pediatrics 148(5): 484, 1989

Effect of long term continuous ambulatory peritoneal dialysis continuous cyclic peritoneal dialysis and peritonitis on the peritoneal membrane function and peritoneal kinetics in children. Kidney International 29(1): 238, 1986

Peritoneal protein loss in patients with high peritoneal permeability: comparison between continuous ambulatory peritoneal dialysis and daytime intermittent peritoneal dialysis. Archives of Medical Research 32(3): 197-201, 2001

Sleep disorders in patients with end-stage renal disease undergoing dialysis: comparison between hemodialysis, continuous ambulatory peritoneal dialysis and automated peritoneal dialysis. International Urology and Nephrology 47(2): 369-375, 2015

Exfoliated mesothelial cell and CA-125 in automated peritoneal dialysis (APD) and continuous ambulatory peritoneal dialysis (CAPD) patients. Journal of the Medical Association of Thailand 94 Suppl 4: S119-S125, 2012

Adequacy of peritoneal dialysis and nutritional status in patients on continuous ambulatory peritoneal dialysis (CAPD). South African Medical Journal 92(11): 887-889, 2003

Growth in children undergoing continuous ambulatory peritoneal dialysis/continuous cycling peritoneal dialysis/automated peritoneal dialysis. Peritoneal Dialysis International 13 Suppl 2: S247-S250, 1993

Comparison of Blood Pressure Control and Left Ventricular Hypertrophy in Patients on Continuous Ambulatory Peritoneal Dialysis (CAPD) and Automated Peritoneal Dialysis (APD). Electrolyte and Blood Pressure 9(1): 16-22, 2011

Low calcium ion peritoneal dialysis solution and intraperitoneal 1 25 dihydroxyvitamin d3 regulate peritoneal immune defense mechanisms in continuous ambulatory peritoneal dialysis long term in vivo studies. Blood Purification 9(1): 30, 1991

CD4/CD8 T-cell ratio in peritoneal dialysis effluents predicts the outcome of peritonitis in patients undergoing continuous ambulatory peritoneal dialysis. Artificial Organs 33(12): 1091-1095, 2010

Effects of a new bicarbonate/lactate-buffered neutral peritoneal dialysis fluid for peritoneal failure in patients undergoing peritoneal dialysis. Discovery Medicine 21(114): 81-88, 2016